Core Laboratories Inc.
CLB
$16.45
$0.342.11%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 134.52M | 130.16M | 123.59M | 129.24M | 134.40M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 134.52M | 130.16M | 123.59M | 129.24M | 134.40M |
| Cost of Revenue | 104.90M | 103.70M | 99.47M | 106.20M | 106.81M |
| Gross Profit | 29.62M | 26.46M | 24.12M | 23.04M | 27.59M |
| SG&A Expenses | 10.38M | 10.16M | 13.37M | 8.79M | 8.33M |
| Depreciation & Amortization | 3.59M | 3.67M | 3.72M | 3.66M | 3.68M |
| Other Operating Expenses | -375.00K | -144.00K | -785.00K | -221.00K | -1.01M |
| Total Operating Expenses | 118.50M | 117.39M | 115.77M | 118.44M | 117.80M |
| Operating Income | 16.03M | 12.77M | 7.82M | 10.80M | 16.60M |
| Income Before Tax | 18.28M | 12.58M | 1.82M | 11.55M | 16.70M |
| Income Tax Expenses | 3.75M | 1.91M | 1.75M | 4.08M | 4.69M |
| Earnings from Continuing Operations | 14.52M | 10.67M | 69.00K | 7.47M | 12.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -285.00K | -33.00K | -223.00K | -66.00K | -259.00K |
| Net Income | 14.24M | 10.64M | -154.00K | 7.40M | 11.75M |
| EBIT | 16.03M | 12.77M | 7.82M | 10.80M | 16.60M |
| EBITDA | 19.62M | 16.44M | 11.53M | 14.47M | 20.27M |
| EPS Basic | 0.31 | 0.23 | 0.00 | 0.16 | 0.25 |
| Normalized Basic EPS | 0.17 | 0.13 | 0.06 | 0.10 | 0.18 |
| EPS Diluted | 0.30 | 0.22 | 0.00 | 0.16 | 0.25 |
| Normalized Diluted EPS | 0.16 | 0.13 | 0.06 | 0.10 | 0.18 |
| Average Basic Shares Outstanding | 46.26M | 46.63M | 46.77M | 47.77M | 46.92M |
| Average Diluted Shares Outstanding | 47.08M | 47.36M | 46.77M | 47.77M | 47.82M |
| Dividend Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Payout Ratio | 3.27% | 4.41% | -304.55% | 6.34% | 3.99% |